{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pandas as pd"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 28,
   "metadata": {},
   "outputs": [],
   "source": [
    "pd.set_option(\"display.max_colwidth\", 0)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>Set_ID</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "      <th>Active_ingredient</th>\n",
       "      <th>UNII_ID</th>\n",
       "      <th>Section</th>\n",
       "      <th>Text</th>\n",
       "      <th>WordCount</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>Drug_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>3fa9bff0-676b-45d9-9d77-a6363c63395f</td>\n",
       "      <td>Omnipaque</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>4419T9MX03</td>\n",
       "      <td>Indications</td>\n",
       "      <td>OMNIPAQUE 300 is indicated for intrathecal adm...</td>\n",
       "      <td>4207</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml</td>\n",
       "      <td>442aed6e-6242-4a96-90aa-d988b62d55e8</td>\n",
       "      <td>Omnipaque</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>4419T9MX03</td>\n",
       "      <td>Indications</td>\n",
       "      <td>OMNIPAQUE 300 is indicated for intrathecal adm...</td>\n",
       "      <td>4207</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>e653596f-6792-4e6b-a50f-2d02b5159a8a.xml</td>\n",
       "      <td>f9e9d558-064c-4b86-8d96-2f8a678c89f9</td>\n",
       "      <td>OMNIPAQUE</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>4419T9MX03</td>\n",
       "      <td>Indications</td>\n",
       "      <td>OMNIPAQUE (iohexol) injection is a radiographi...</td>\n",
       "      <td>365</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>daf75b73-a930-4baa-8b04-703c9f89e2e7.xml</td>\n",
       "      <td>eee15ebe-d349-4497-acef-6abe7a8247fb</td>\n",
       "      <td>OMNIPAQUE</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>4419T9MX03</td>\n",
       "      <td>Indications</td>\n",
       "      <td>OMNIPAQUE (iohexol) injection is a radiographi...</td>\n",
       "      <td>365</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>3fa9bff0-676b-45d9-9d77-a6363c63395f</td>\n",
       "      <td>Omnipaque</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>4419T9MX03</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>OMNIPAQUE should not be administered to patien...</td>\n",
       "      <td>157</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Label_ID  \\\n",
       "0  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml   \n",
       "1  2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml   \n",
       "2  e653596f-6792-4e6b-a50f-2d02b5159a8a.xml   \n",
       "3  daf75b73-a930-4baa-8b04-703c9f89e2e7.xml   \n",
       "4  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml   \n",
       "\n",
       "                                 Set_ID Drug_Brand_Name Active_ingredient  \\\n",
       "0  3fa9bff0-676b-45d9-9d77-a6363c63395f       Omnipaque           Iohexol   \n",
       "1  442aed6e-6242-4a96-90aa-d988b62d55e8       Omnipaque           Iohexol   \n",
       "2  f9e9d558-064c-4b86-8d96-2f8a678c89f9       OMNIPAQUE           Iohexol   \n",
       "3  eee15ebe-d349-4497-acef-6abe7a8247fb       OMNIPAQUE           Iohexol   \n",
       "4  3fa9bff0-676b-45d9-9d77-a6363c63395f       Omnipaque           Iohexol   \n",
       "\n",
       "      UNII_ID            Section  \\\n",
       "0  4419T9MX03        Indications   \n",
       "1  4419T9MX03        Indications   \n",
       "2  4419T9MX03        Indications   \n",
       "3  4419T9MX03        Indications   \n",
       "4  4419T9MX03  Contraindications   \n",
       "\n",
       "                                                Text  WordCount    DB_ID  \\\n",
       "0  OMNIPAQUE 300 is indicated for intrathecal adm...       4207  DB01362   \n",
       "1  OMNIPAQUE 300 is indicated for intrathecal adm...       4207  DB01362   \n",
       "2  OMNIPAQUE (iohexol) injection is a radiographi...        365  DB01362   \n",
       "3  OMNIPAQUE (iohexol) injection is a radiographi...        365  DB01362   \n",
       "4  OMNIPAQUE should not be administered to patien...        157  DB01362   \n",
       "\n",
       "  Drug_name  \n",
       "0   Iohexol  \n",
       "1   Iohexol  \n",
       "2   Iohexol  \n",
       "3   Iohexol  \n",
       "4   Iohexol  "
      ]
     },
     "execution_count": 2,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "xml_df = pd.read_csv('/data/output/XMLProduct_DBID.csv')\n",
    "xml_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 23,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>From</th>\n",
       "      <th>To</th>\n",
       "      <th>Type</th>\n",
       "      <th>Annotation</th>\n",
       "      <th>Context</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DrugName</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>63</td>\n",
       "      <td>78</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patien...</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>516</td>\n",
       "      <td>531</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patien...</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>608</td>\n",
       "      <td>623</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patien...</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml</td>\n",
       "      <td>63</td>\n",
       "      <td>78</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patien...</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml</td>\n",
       "      <td>516</td>\n",
       "      <td>531</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patien...</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Label_ID  From   To Type        Annotation  \\\n",
       "0  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml    63   78  SYN  HYPERSENSITIVITY   \n",
       "1  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml   516  531  SYN  HYPERSENSITIVITY   \n",
       "2  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml   608  623  SYN  HYPERSENSITIVITY   \n",
       "3  2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml    63   78  SYN  HYPERSENSITIVITY   \n",
       "4  2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml   516  531  SYN  HYPERSENSITIVITY   \n",
       "\n",
       "                                             Context  \\\n",
       "0  OMNIPAQUE should not be administered to patien...   \n",
       "1  OMNIPAQUE should not be administered to patien...   \n",
       "2  OMNIPAQUE should not be administered to patien...   \n",
       "3  OMNIPAQUE should not be administered to patien...   \n",
       "4  OMNIPAQUE should not be administered to patien...   \n",
       "\n",
       "                                      DO_ID    DB_ID DrugName Drug_Brand_Name  \n",
       "0  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol       Omnipaque  \n",
       "1  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol       Omnipaque  \n",
       "2  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol       Omnipaque  \n",
       "3  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol       Omnipaque  \n",
       "4  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol       Omnipaque  "
      ]
     },
     "execution_count": 23,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "unlabelled = pd.read_csv('/data/output/XMLProduct_annotations.csv')\n",
    "unlabelled.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 24,
   "metadata": {},
   "outputs": [],
   "source": [
    "xml_df = xml_df[['Label_ID','Set_ID','UNII_ID','Section','Text']]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 25,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/jovyan/.local/lib/python3.7/site-packages/pandas/core/frame.py:4238: SettingWithCopyWarning: \n",
      "A value is trying to be set on a copy of a slice from a DataFrame\n",
      "\n",
      "See the caveats in the documentation: http://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n",
      "  return super().rename(**kwargs)\n"
     ]
    }
   ],
   "source": [
    "xml_df.rename(columns={'Text':'Context'}, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 26,
   "metadata": {},
   "outputs": [],
   "source": [
    "unlabelled =unlabelled.merge(xml_df, on=['Label_ID','Context'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 27,
   "metadata": {},
   "outputs": [],
   "source": [
    "unlabelled.DO_ID = unlabelled.DO_ID.str.replace('http://purl.obolibrary.org/obo/','')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 39,
   "metadata": {},
   "outputs": [],
   "source": [
    "unlabelled= unlabelled.drop_duplicates(subset=['Context','DO_ID'], keep='first')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 40,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>From</th>\n",
       "      <th>To</th>\n",
       "      <th>Type</th>\n",
       "      <th>Annotation</th>\n",
       "      <th>Context</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DrugName</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "      <th>Set_ID</th>\n",
       "      <th>UNII_ID</th>\n",
       "      <th>Section</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>63</td>\n",
       "      <td>78</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.</td>\n",
       "      <td>DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "      <td>3fa9bff0-676b-45d9-9d77-a6363c63395f</td>\n",
       "      <td>4419T9MX03</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>96b03338-adb6-ffc8-e053-2995a90a90a6.xml</td>\n",
       "      <td>53</td>\n",
       "      <td>68</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>Oraltag is contraindicated in patients with a known hypersensitivity to iodinated contrast agents, including iohexol \\r\\n[see \\r\\nWarnings and Precautions (5.2)\\r\\nHypersensitivity to iodinated contrast agents, including iohexol</td>\n",
       "      <td>DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>IOHEXOL</td>\n",
       "      <td>ORALTAG</td>\n",
       "      <td>fdeb1668-7126-48f7-aaf9-1dc3beb90bac</td>\n",
       "      <td>4419T9MX03</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>8</th>\n",
       "      <td>cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml</td>\n",
       "      <td>349</td>\n",
       "      <td>364</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.</td>\n",
       "      <td>DOID_1205</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>RIBAVIRIN</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>3b8b0c65-e466-4662-9e85-5a253d31ebe8</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>10</th>\n",
       "      <td>cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml</td>\n",
       "      <td>427</td>\n",
       "      <td>446</td>\n",
       "      <td>PREF</td>\n",
       "      <td>AUTOIMMUNE HEPATITIS</td>\n",
       "      <td>Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.</td>\n",
       "      <td>DOID_2048</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>RIBAVIRIN</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>3b8b0c65-e466-4662-9e85-5a253d31ebe8</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>12</th>\n",
       "      <td>cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml</td>\n",
       "      <td>555</td>\n",
       "      <td>563</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HEPATITIS</td>\n",
       "      <td>Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.</td>\n",
       "      <td>DOID_2237</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>RIBAVIRIN</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>3b8b0c65-e466-4662-9e85-5a253d31ebe8</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>13</th>\n",
       "      <td>cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml</td>\n",
       "      <td>587</td>\n",
       "      <td>604</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HEMOGLOBINOPATHIES</td>\n",
       "      <td>Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.</td>\n",
       "      <td>DOID_2860</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>RIBAVIRIN</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>3b8b0c65-e466-4662-9e85-5a253d31ebe8</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>14</th>\n",
       "      <td>cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml</td>\n",
       "      <td>613</td>\n",
       "      <td>623</td>\n",
       "      <td>PREF</td>\n",
       "      <td>THALASSEMIA</td>\n",
       "      <td>Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.</td>\n",
       "      <td>DOID_10241</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>RIBAVIRIN</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>3b8b0c65-e466-4662-9e85-5a253d31ebe8</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>15</th>\n",
       "      <td>cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml</td>\n",
       "      <td>644</td>\n",
       "      <td>649</td>\n",
       "      <td>PREF</td>\n",
       "      <td>ANEMIA</td>\n",
       "      <td>Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.</td>\n",
       "      <td>DOID_2355</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>RIBAVIRIN</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>3b8b0c65-e466-4662-9e85-5a253d31ebe8</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Contraindications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>16</th>\n",
       "      <td>700cdb41-e8fc-41f5-82d7-868369709b26.xml</td>\n",
       "      <td>465</td>\n",
       "      <td>471</td>\n",
       "      <td>PREF</td>\n",
       "      <td>DISEASE</td>\n",
       "      <td>Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.\\r\\nOnly severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection.\\r\\nUse of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see \\r\\nWARNINGS\\r\\nDOSAGE AND ADMINISTRATION\\r\\n \\r\\nDiagnosis\\r\\nRSV infection should be documented by a rapid diagnostic method such as demonstration of viral antigen in respiratory tract secretions by immunofluorescence\\r\\n3,4\\r\\n5\\r\\n \\r\\n \\r\\nNon-Mechanically Ventilated Infants:\\r\\n3,4\\r\\n4\\r\\n \\r\\n \\r\\nMechanically Ventilated Infants:\\r\\n6\\r\\nl\\r\\n2\\r\\n(r)\\r\\nEmploying these techniques, no technical difficulties with Ribavirin for Inhalation Solution, USP administration were encountered during the study. Adverse events consisted of bacterial pneumonia in one case, staphylococcus bacteremia in one case and two cases of post-extubation stridor. None were felt to be related to Ribavirin for Inhalation Solution, USP administration.</td>\n",
       "      <td>DOID_4</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>d74aa4f3-0b7d-480d-b5bf-41ddf808b260</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Indications</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>17</th>\n",
       "      <td>700cdb41-e8fc-41f5-82d7-868369709b26.xml</td>\n",
       "      <td>1012</td>\n",
       "      <td>1034</td>\n",
       "      <td>SYN</td>\n",
       "      <td>CARDIOPULMONARY DISEASE</td>\n",
       "      <td>Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.\\r\\nOnly severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection.\\r\\nUse of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see \\r\\nWARNINGS\\r\\nDOSAGE AND ADMINISTRATION\\r\\n \\r\\nDiagnosis\\r\\nRSV infection should be documented by a rapid diagnostic method such as demonstration of viral antigen in respiratory tract secretions by immunofluorescence\\r\\n3,4\\r\\n5\\r\\n \\r\\n \\r\\nNon-Mechanically Ventilated Infants:\\r\\n3,4\\r\\n4\\r\\n \\r\\n \\r\\nMechanically Ventilated Infants:\\r\\n6\\r\\nl\\r\\n2\\r\\n(r)\\r\\nEmploying these techniques, no technical difficulties with Ribavirin for Inhalation Solution, USP administration were encountered during the study. Adverse events consisted of bacterial pneumonia in one case, staphylococcus bacteremia in one case and two cases of post-extubation stridor. None were felt to be related to Ribavirin for Inhalation Solution, USP administration.</td>\n",
       "      <td>DOID_8515</td>\n",
       "      <td>DB00811</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>Ribavirin</td>\n",
       "      <td>d74aa4f3-0b7d-480d-b5bf-41ddf808b260</td>\n",
       "      <td>49717AWG6K</td>\n",
       "      <td>Indications</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                    Label_ID  From    To  Type  \\\n",
       "0   9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml  63    78    SYN    \n",
       "6   96b03338-adb6-ffc8-e053-2995a90a90a6.xml  53    68    SYN    \n",
       "8   cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml  349   364   SYN    \n",
       "10  cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml  427   446   PREF   \n",
       "12  cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml  555   563   PREF   \n",
       "13  cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml  587   604   SYN    \n",
       "14  cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml  613   623   PREF   \n",
       "15  cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml  644   649   PREF   \n",
       "16  700cdb41-e8fc-41f5-82d7-868369709b26.xml  465   471   PREF   \n",
       "17  700cdb41-e8fc-41f5-82d7-868369709b26.xml  1012  1034  SYN    \n",
       "\n",
       "                 Annotation  \\\n",
       "0   HYPERSENSITIVITY          \n",
       "6   HYPERSENSITIVITY          \n",
       "8   HYPERSENSITIVITY          \n",
       "10  AUTOIMMUNE HEPATITIS      \n",
       "12  HEPATITIS                 \n",
       "13  HEMOGLOBINOPATHIES        \n",
       "14  THALASSEMIA               \n",
       "15  ANEMIA                    \n",
       "16  DISEASE                   \n",
       "17  CARDIOPULMONARY DISEASE   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       Context  \\\n",
       "0   OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    \n",
       "6   Oraltag is contraindicated in patients with a known hypersensitivity to iodinated contrast agents, including iohexol \\r\\n[see \\r\\nWarnings and Precautions (5.2)\\r\\nHypersensitivity to iodinated contrast agents, including iohexol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \n",
       "8   Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.   \n",
       "10  Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.   \n",
       "12  Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.   \n",
       "13  Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.   \n",
       "14  Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.   \n",
       "15  Ribavirin capsules may cause birth defects and/or death of the exposed fetus. Ribavirin therapy is contraindicated for use in women who are pregnant or in men whose female partners are pregnant. (See \\r\\n \\r\\nWARNINGS\\r\\nPRECAUTIONS\\r\\nInformation for Patients\\r\\n \\r\\nPregnancy Category X\\r\\nRibavirin capsules are contraindicated in patients with a history of hypersensitivity to ribavirin or any component of the capsule.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin/INTRON A therapy because using these medicines can make the hepatitis worse.\\r\\nPatients with hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia) should not be treated with ribavirin capsules.\\r\\nCombination ribavirin capsules/INTRON A therapy must not be used by females who are pregnant or by males whose female partners are pregnant. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients taking combination ribavirin capsules/INTRON A therapy. Combination ribavirin capsules/INTRON A therapy should not be initiated until a report of a negative pregnancy test has been obtained immediately prior to initiation of therapy. Females of childbearing potential and males must use two forms of effective contraception during treatment and during the 6 months after treatment has been concluded. Significant teratogenic and/or embryocidal effects have been demonstrated for ribavirin in all animal species in which adequate studies have been conducted. These effects occurred at doses as low as one twentieth of the recommended human dose of ribavirin capsules. If pregnancy occurs in a patient or partner of a patient during treatment or during the 6 months after treatment stops, physicians are encouraged to report such cases by calling the Ribavirin Pregnancy Registry at 1-800-593-2214. \\r\\nSee boxed CONTRAINDICATIONS AND WARNINGS. See \\r\\nWARNINGS\\r\\nRibavirin capsules in combination with INTRON A Injection is contraindicated in patients with a history of hypersensitivity to ribavirin and/or alpha interferon or any component of the capsule and/or injection.\\r\\nPatients with autoimmune hepatitis must not be treated with combination ribavirin capsules/INTRON A therapy.   \n",
       "16  Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.\\r\\nOnly severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection.\\r\\nUse of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see \\r\\nWARNINGS\\r\\nDOSAGE AND ADMINISTRATION\\r\\n \\r\\nDiagnosis\\r\\nRSV infection should be documented by a rapid diagnostic method such as demonstration of viral antigen in respiratory tract secretions by immunofluorescence\\r\\n3,4\\r\\n5\\r\\n \\r\\n \\r\\nNon-Mechanically Ventilated Infants:\\r\\n3,4\\r\\n4\\r\\n \\r\\n \\r\\nMechanically Ventilated Infants:\\r\\n6\\r\\nl\\r\\n2\\r\\n(r)\\r\\nEmploying these techniques, no technical difficulties with Ribavirin for Inhalation Solution, USP administration were encountered during the study. Adverse events consisted of bacterial pneumonia in one case, staphylococcus bacteremia in one case and two cases of post-extubation stridor. None were felt to be related to Ribavirin for Inhalation Solution, USP administration.                                                                                                                               \n",
       "17  Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy.\\r\\nOnly severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection.\\r\\nUse of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see \\r\\nWARNINGS\\r\\nDOSAGE AND ADMINISTRATION\\r\\n \\r\\nDiagnosis\\r\\nRSV infection should be documented by a rapid diagnostic method such as demonstration of viral antigen in respiratory tract secretions by immunofluorescence\\r\\n3,4\\r\\n5\\r\\n \\r\\n \\r\\nNon-Mechanically Ventilated Infants:\\r\\n3,4\\r\\n4\\r\\n \\r\\n \\r\\nMechanically Ventilated Infants:\\r\\n6\\r\\nl\\r\\n2\\r\\n(r)\\r\\nEmploying these techniques, no technical difficulties with Ribavirin for Inhalation Solution, USP administration were encountered during the study. Adverse events consisted of bacterial pneumonia in one case, staphylococcus bacteremia in one case and two cases of post-extubation stridor. None were felt to be related to Ribavirin for Inhalation Solution, USP administration.                                                                                                                               \n",
       "\n",
       "         DO_ID    DB_ID   DrugName Drug_Brand_Name  \\\n",
       "0   DOID_1205   DB01362  Iohexol    Omnipaque        \n",
       "6   DOID_1205   DB01362  IOHEXOL    ORALTAG          \n",
       "8   DOID_1205   DB00811  RIBAVIRIN  Ribavirin        \n",
       "10  DOID_2048   DB00811  RIBAVIRIN  Ribavirin        \n",
       "12  DOID_2237   DB00811  RIBAVIRIN  Ribavirin        \n",
       "13  DOID_2860   DB00811  RIBAVIRIN  Ribavirin        \n",
       "14  DOID_10241  DB00811  RIBAVIRIN  Ribavirin        \n",
       "15  DOID_2355   DB00811  RIBAVIRIN  Ribavirin        \n",
       "16  DOID_4      DB00811  Ribavirin  Ribavirin        \n",
       "17  DOID_8515   DB00811  Ribavirin  Ribavirin        \n",
       "\n",
       "                                  Set_ID     UNII_ID            Section  \n",
       "0   3fa9bff0-676b-45d9-9d77-a6363c63395f  4419T9MX03  Contraindications  \n",
       "6   fdeb1668-7126-48f7-aaf9-1dc3beb90bac  4419T9MX03  Contraindications  \n",
       "8   3b8b0c65-e466-4662-9e85-5a253d31ebe8  49717AWG6K  Contraindications  \n",
       "10  3b8b0c65-e466-4662-9e85-5a253d31ebe8  49717AWG6K  Contraindications  \n",
       "12  3b8b0c65-e466-4662-9e85-5a253d31ebe8  49717AWG6K  Contraindications  \n",
       "13  3b8b0c65-e466-4662-9e85-5a253d31ebe8  49717AWG6K  Contraindications  \n",
       "14  3b8b0c65-e466-4662-9e85-5a253d31ebe8  49717AWG6K  Contraindications  \n",
       "15  3b8b0c65-e466-4662-9e85-5a253d31ebe8  49717AWG6K  Contraindications  \n",
       "16  d74aa4f3-0b7d-480d-b5bf-41ddf808b260  49717AWG6K  Indications        \n",
       "17  d74aa4f3-0b7d-480d-b5bf-41ddf808b260  49717AWG6K  Indications        "
      ]
     },
     "execution_count": 40,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "unlabelled.head(10)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>DBID</th>\n",
       "      <th>DOID</th>\n",
       "      <th>disease</th>\n",
       "      <th>drug</th>\n",
       "      <th>label_id</th>\n",
       "      <th>relation</th>\n",
       "      <th>text</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>0</td>\n",
       "      <td>DB00657</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Mecamylamine</td>\n",
       "      <td>976f404f-4857-4bad-9a3c-9bf3d5ca9f5b.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>For the management of moderately severe to sev...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>1</td>\n",
       "      <td>DB00401</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Nisoldipine</td>\n",
       "      <td>ce733b39-7857-4538-92d6-1c68a4e4eb75.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Nisoldipine extended-release tablets are indic...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>2</td>\n",
       "      <td>DB00612</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Bisoprolol</td>\n",
       "      <td>c818c38d-ee37-4ceb-b078-611483b4f743.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Bisoprolol fumarate tablets, USP are indicated...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>3</td>\n",
       "      <td>DB00960</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Pindolol</td>\n",
       "      <td>d4078b63-30ad-435b-a081-4d90562962b5.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Pindolol tablets are indicated in the manageme...</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>4</td>\n",
       "      <td>DB00876</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Eprosartan</td>\n",
       "      <td>ab531d28-345b-4113-9fde-00cd63ad5b1a.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Eprosartan mesylate tablets are indicated for ...</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0     DBID        DOID       disease          drug  \\\n",
       "0           0  DB00657  DOID_10763  hypertension  Mecamylamine   \n",
       "1           1  DB00401  DOID_10763  hypertension   Nisoldipine   \n",
       "2           2  DB00612  DOID_10763  hypertension    Bisoprolol   \n",
       "3           3  DB00960  DOID_10763  hypertension      Pindolol   \n",
       "4           4  DB00876  DOID_10763  hypertension    Eprosartan   \n",
       "\n",
       "                                   label_id   relation  \\\n",
       "0  976f404f-4857-4bad-9a3c-9bf3d5ca9f5b.xml  treatment   \n",
       "1  ce733b39-7857-4538-92d6-1c68a4e4eb75.xml  treatment   \n",
       "2  c818c38d-ee37-4ceb-b078-611483b4f743.xml  treatment   \n",
       "3  d4078b63-30ad-435b-a081-4d90562962b5.xml  treatment   \n",
       "4  ab531d28-345b-4113-9fde-00cd63ad5b1a.xml  treatment   \n",
       "\n",
       "                                                text  \n",
       "0  For the management of moderately severe to sev...  \n",
       "1  Nisoldipine extended-release tablets are indic...  \n",
       "2  Bisoprolol fumarate tablets, USP are indicated...  \n",
       "3  Pindolol tablets are indicated in the manageme...  \n",
       "4  Eprosartan mesylate tablets are indicated for ...  "
      ]
     },
     "execution_count": 5,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "crowd = pd.read_csv('/data/output/crowd_all.csv')\n",
    "crowd.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "3256\n",
      "3256\n"
     ]
    }
   ],
   "source": [
    "print (len(crowd))\n",
    "crowd = crowd.dropna(subset=['label_id'])\n",
    "print (len(crowd))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 16,
   "metadata": {},
   "outputs": [],
   "source": [
    "crowd['Section'] = 'Indications'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 17,
   "metadata": {},
   "outputs": [],
   "source": [
    "index= crowd.label_id.str.contains('./DailyMedExtracter/prescription/')\n",
    "crowd.loc[index,'Section']=  'Contraindications'"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 21,
   "metadata": {},
   "outputs": [],
   "source": [
    "crowd.loc[index,'label_id'] = crowd.loc[index,'label_id'].str.replace('../DailyMedExtracter/prescription/temp_xml/','')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 33,
   "metadata": {},
   "outputs": [],
   "source": [
    "crowd =crowd.rename(columns={'DOID':'DO_ID','DBID':'DB_ID','label_id':'Label_ID'})"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 34,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>disease</th>\n",
       "      <th>drug</th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>relation</th>\n",
       "      <th>text</th>\n",
       "      <th>Section</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>253</th>\n",
       "      <td>253</td>\n",
       "      <td>DB00695</td>\n",
       "      <td>DOID_11396</td>\n",
       "      <td>pulmonary edema</td>\n",
       "      <td>Furosemide</td>\n",
       "      <td>bd75b5e2-d541-423a-a965-85d2197c6595.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical.</td>\n",
       "      <td>Indications</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "     Unnamed: 0    DB_ID       DO_ID          disease        drug  \\\n",
       "253  253         DB00695  DOID_11396  pulmonary edema  Furosemide   \n",
       "\n",
       "                                     Label_ID   relation  \\\n",
       "253  bd75b5e2-d541-423a-a965-85d2197c6595.xml  treatment   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               text  \\\n",
       "253  Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations.Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical.   \n",
       "\n",
       "         Section  \n",
       "253  Indications  "
      ]
     },
     "execution_count": 34,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "crowd.sample()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 35,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "3256"
      ]
     },
     "execution_count": 35,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(crowd)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 41,
   "metadata": {},
   "outputs": [],
   "source": [
    "match = crowd.merge(unlabelled, on=['DB_ID','DO_ID','Label_ID','Section'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 42,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>disease</th>\n",
       "      <th>drug</th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>relation</th>\n",
       "      <th>text</th>\n",
       "      <th>Section</th>\n",
       "      <th>From</th>\n",
       "      <th>To</th>\n",
       "      <th>Type</th>\n",
       "      <th>Annotation</th>\n",
       "      <th>Context</th>\n",
       "      <th>DrugName</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "      <th>Set_ID</th>\n",
       "      <th>UNII_ID</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>1</td>\n",
       "      <td>DB00401</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Nisoldipine</td>\n",
       "      <td>ce733b39-7857-4538-92d6-1c68a4e4eb75.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Nisoldipine extended-release tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>73</td>\n",
       "      <td>84</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>Nisoldipine extended-release tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.</td>\n",
       "      <td>NISOLDIPINE</td>\n",
       "      <td>Nisoldipine</td>\n",
       "      <td>a6a8a8ba-3966-4f37-a58b-44d3b05bdc4e</td>\n",
       "      <td>4I8HAB65SZ</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>4</td>\n",
       "      <td>DB00876</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Eprosartan</td>\n",
       "      <td>ab531d28-345b-4113-9fde-00cd63ad5b1a.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Eprosartan mesylate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>64</td>\n",
       "      <td>75</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>Eprosartan mesylate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers.</td>\n",
       "      <td>EPROSARTAN</td>\n",
       "      <td>Eprosartan Mesylate</td>\n",
       "      <td>64fbc500-3b77-4c9c-8576-b3ec5f6655a5</td>\n",
       "      <td>2KH13Z0S0Y</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>6</td>\n",
       "      <td>DB00373</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Timolol</td>\n",
       "      <td>87fe4811-1f32-ae9e-e053-2a95a90a9f1d.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Hypertension Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Myocardial Infarction Timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.Migraine Timolol is indicated for the prophylaxis of migraine headache.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>3</td>\n",
       "      <td>14</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>\\r\\nHypertension\\r\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\r\\n \\r\\nMyocardial Infarction\\r\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\r\\n \\r\\nMigraine\\r\\nTimolol is indicated for the prophylaxis of migraine headache.</td>\n",
       "      <td>TIMOLOL ANHYDROUS</td>\n",
       "      <td>Timolol Maleate</td>\n",
       "      <td>8d2c2bf4-7644-47ec-b72e-a414c4d7c6e8</td>\n",
       "      <td>5JKY92S7BR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>437</td>\n",
       "      <td>DB00373</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Timolol</td>\n",
       "      <td>87fe4811-1f32-ae9e-e053-2a95a90a9f1d.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Hypertension\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\n\\n\\nMyocardial Infarction\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\n\\n\\nMigraine\\nTimolol is indicated for the prophylaxis of migraine headache.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>3</td>\n",
       "      <td>14</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>\\r\\nHypertension\\r\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\r\\n \\r\\nMyocardial Infarction\\r\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\r\\n \\r\\nMigraine\\r\\nTimolol is indicated for the prophylaxis of migraine headache.</td>\n",
       "      <td>TIMOLOL ANHYDROUS</td>\n",
       "      <td>Timolol Maleate</td>\n",
       "      <td>8d2c2bf4-7644-47ec-b72e-a414c4d7c6e8</td>\n",
       "      <td>5JKY92S7BR</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>1266</td>\n",
       "      <td>DB00373</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>drug</td>\n",
       "      <td>87fe4811-1f32-ae9e-e053-2a95a90a9f1d.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>HypertensionTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Myocardial InfarctionTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.MigraineTimolol is indicated for the prophylaxis of migraine headache.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>3</td>\n",
       "      <td>14</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>\\r\\nHypertension\\r\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\r\\n \\r\\nMyocardial Infarction\\r\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\r\\n \\r\\nMigraine\\r\\nTimolol is indicated for the prophylaxis of migraine headache.</td>\n",
       "      <td>TIMOLOL ANHYDROUS</td>\n",
       "      <td>Timolol Maleate</td>\n",
       "      <td>8d2c2bf4-7644-47ec-b72e-a414c4d7c6e8</td>\n",
       "      <td>5JKY92S7BR</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0    DB_ID       DO_ID       disease         drug  \\\n",
       "0  1           DB00401  DOID_10763  hypertension  Nisoldipine   \n",
       "1  4           DB00876  DOID_10763  hypertension  Eprosartan    \n",
       "2  6           DB00373  DOID_10763  hypertension  Timolol       \n",
       "3  437         DB00373  DOID_10763  hypertension  Timolol       \n",
       "4  1266        DB00373  DOID_10763  hypertension  drug          \n",
       "\n",
       "                                   Label_ID   relation  \\\n",
       "0  ce733b39-7857-4538-92d6-1c68a4e4eb75.xml  treatment   \n",
       "1  ab531d28-345b-4113-9fde-00cd63ad5b1a.xml  treatment   \n",
       "2  87fe4811-1f32-ae9e-e053-2a95a90a9f1d.xml  treatment   \n",
       "3  87fe4811-1f32-ae9e-e053-2a95a90a9f1d.xml  treatment   \n",
       "4  87fe4811-1f32-ae9e-e053-2a95a90a9f1d.xml  treatment   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         text  \\\n",
       "0  Nisoldipine extended-release tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.                                                                                                                                                                                                                                                                                                                                           \n",
       "1  Eprosartan mesylate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers.                                                                                                                                                                                                                                                                                                           \n",
       "2  Hypertension Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Myocardial Infarction Timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.Migraine Timolol is indicated for the prophylaxis of migraine headache.                  \n",
       "3  Hypertension\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\n\\n\\nMyocardial Infarction\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\n\\n\\nMigraine\\nTimolol is indicated for the prophylaxis of migraine headache.   \n",
       "4  HypertensionTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.Myocardial InfarctionTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.MigraineTimolol is indicated for the prophylaxis of migraine headache.                     \n",
       "\n",
       "       Section  From  To  Type    Annotation  \\\n",
       "0  Indications  73    84  PREF  HYPERTENSION   \n",
       "1  Indications  64    75  PREF  HYPERTENSION   \n",
       "2  Indications  3     14  PREF  HYPERTENSION   \n",
       "3  Indications  3     14  PREF  HYPERTENSION   \n",
       "4  Indications  3     14  PREF  HYPERTENSION   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      Context  \\\n",
       "0  Nisoldipine extended-release tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents.                                                                                                                                                                                                                                                                                                                                                           \n",
       "1  Eprosartan mesylate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensives such as diuretics and calcium channel blockers.                                                                                                                                                                                                                                                                                                                           \n",
       "2  \\r\\nHypertension\\r\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\r\\n \\r\\nMyocardial Infarction\\r\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\r\\n \\r\\nMigraine\\r\\nTimolol is indicated for the prophylaxis of migraine headache.   \n",
       "3  \\r\\nHypertension\\r\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\r\\n \\r\\nMyocardial Infarction\\r\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\r\\n \\r\\nMigraine\\r\\nTimolol is indicated for the prophylaxis of migraine headache.   \n",
       "4  \\r\\nHypertension\\r\\nTimolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics.\\r\\n \\r\\nMyocardial Infarction\\r\\nTimolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction.\\r\\n \\r\\nMigraine\\r\\nTimolol is indicated for the prophylaxis of migraine headache.   \n",
       "\n",
       "            DrugName      Drug_Brand_Name  \\\n",
       "0  NISOLDIPINE        Nisoldipine           \n",
       "1  EPROSARTAN         Eprosartan Mesylate   \n",
       "2  TIMOLOL ANHYDROUS  Timolol Maleate       \n",
       "3  TIMOLOL ANHYDROUS  Timolol Maleate       \n",
       "4  TIMOLOL ANHYDROUS  Timolol Maleate       \n",
       "\n",
       "                                 Set_ID     UNII_ID  \n",
       "0  a6a8a8ba-3966-4f37-a58b-44d3b05bdc4e  4I8HAB65SZ  \n",
       "1  64fbc500-3b77-4c9c-8576-b3ec5f6655a5  2KH13Z0S0Y  \n",
       "2  8d2c2bf4-7644-47ec-b72e-a414c4d7c6e8  5JKY92S7BR  \n",
       "3  8d2c2bf4-7644-47ec-b72e-a414c4d7c6e8  5JKY92S7BR  \n",
       "4  8d2c2bf4-7644-47ec-b72e-a414c4d7c6e8  5JKY92S7BR  "
      ]
     },
     "execution_count": 42,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "match.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 43,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1552"
      ]
     },
     "execution_count": 43,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(match)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 44,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "73054"
      ]
     },
     "execution_count": 44,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(unlabelled)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 46,
   "metadata": {},
   "outputs": [],
   "source": [
    "all_label_ids = unlabelled.Label_ID.unique()\n",
    "missing =crowd[~crowd.Label_ID.isin(all_label_ids)]"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 83,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "1023"
      ]
     },
     "execution_count": 83,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(crowd.Label_ID.unique())"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 49,
   "metadata": {},
   "outputs": [],
   "source": [
    "import urllib\n",
    "import shutil\n",
    "import os"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 88,
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "http://www.accessdata.fda.gov/spl/data/00bdb48f-8b8f-4cc5-bb63-77213f2279cb/00bdb48f-8b8f-4cc5-bb63-77213f2279cb.xml\n",
      "http://www.accessdata.fda.gov/spl/data/230ef06f-75a4-4bc7-942c-63ab2c7cbec8/230ef06f-75a4-4bc7-942c-63ab2c7cbec8.xml\n",
      "http://www.accessdata.fda.gov/spl/data/8d38d308-d218-4f4e-b7bf-e29acb3a8c56/8d38d308-d218-4f4e-b7bf-e29acb3a8c56.xml\n",
      "http://www.accessdata.fda.gov/spl/data/cbb7cff7-62dd-4bb5-aee5-4202eb730940/cbb7cff7-62dd-4bb5-aee5-4202eb730940.xml\n",
      "http://www.accessdata.fda.gov/spl/data/81541aeb-baaa-5390-e053-2991aa0a5286/81541aeb-baaa-5390-e053-2991aa0a5286.xml\n",
      "http://www.accessdata.fda.gov/spl/data/88048960-8979-4063-8bbf-6000b8cf3c1a/88048960-8979-4063-8bbf-6000b8cf3c1a.xml\n"
     ]
    }
   ],
   "source": [
    "dir_ = '/data/xml'\n",
    "for label_name in crowd.Label_ID.unique():\n",
    "    #label_name = row['Label_ID']\n",
    "    url='http://www.accessdata.fda.gov/spl/data/'+label_name[:-4]+'/'+label_name\n",
    "    #print (url)\n",
    "    try:\n",
    "        with urllib.request.urlopen(url) as response:\n",
    "            with open(os.path.join(dir_,label_name),'wb') as tmp_file:\n",
    "                shutil.copyfileobj(response, tmp_file)\n",
    "    except:\n",
    "        print (url)\n",
    "        pass"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 53,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>Set_ID</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "      <th>Active_ingredient</th>\n",
       "      <th>UNII_ID</th>\n",
       "      <th>Section</th>\n",
       "      <th>Text</th>\n",
       "      <th>WordCount</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>Drug_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>f0e16cc6-966d-4e3c-99c9-29a45d3480dc.xml</td>\n",
       "      <td>80e736d3-2017-4d68-94b4-38255c3c59c6</td>\n",
       "      <td>Cuprimine</td>\n",
       "      <td>Penicillamine</td>\n",
       "      <td>GNN1DV99GX</td>\n",
       "      <td>Indications</td>\n",
       "      <td>CUPRIMINE is indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis. \\r\\nWilson's disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal-recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. \\r\\nTwo types of patients require treatment for Wilson's disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. \\r\\nThe diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is less than 20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (greater than 250 mcg/g dry weight) or Kayser-Fleischer rings are present. \\r\\nTreatment has two objectives: \\r\\n \\r\\n \\r\\n(1)\\r\\n \\r\\n(2)\\r\\nThe first objective is attained by a daily diet that contains no more than 1 or 2 mg of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient's drinking water contains more than 0.1 mg/L of copper. \\r\\nFor the second objective, a copper chelating agent is used. \\r\\nIn symptomatic patients, this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. \\r\\nClinical experience to date suggests that life is prolonged with the above regimen. \\r\\nNoticeable improvement may not occur for 1 to 3 months. Occasionally, neurologic symptoms become worse during initiation of therapy with CUPRIMINE. Despite this, the drug should not be withdrawn. Temporary interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see \\r\\nWARNINGS\\r\\nTreatment of asymptomatic patients has been carried out for over 30 years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with CUPRIMINE is continued. \\r\\nCystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal-recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction. \\r\\nArginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities. \\r\\nCystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria. \\r\\nNormal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated.\\r\\nConventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine-specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see \\r\\nPRECAUTIONS\\r\\nWhen these measures are inadequate to control recurrent stone formation, CUPRIMINE may be used as additional therapy, and when patients refuse to adhere to conventional treatment, CUPRIMINE may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients. Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillamine-cysteine mixed disulfide as:\\r\\n \\r\\n \\r\\n \\r\\n \\r\\n \\r\\nCSSC + PS'\\r\\n \\r\\n \\r\\n \\r\\nCS' + CSSP\\r\\n \\r\\n \\r\\n \\r\\nPSSP + CS'\\r\\n \\r\\n \\r\\n \\r\\nPS' + CSSP\\r\\n \\r\\n \\r\\n \\r\\nCSSC + PSSP'\\r\\n \\r\\n \\r\\n \\r\\n2CSSP\\r\\n \\r\\n \\r\\n \\r\\nCSSC = cystine\\r\\n \\r\\n \\r\\n \\r\\nCS' = deprotonated cysteine\\r\\n \\r\\n \\r\\n \\r\\nPSSP = penicillamine disulfide\\r\\n \\r\\n \\r\\n \\r\\nPS' = deprotonated penicillamine sulfhydryl\\r\\n \\r\\n \\r\\n \\r\\nCSSP = penicillamine-cysteine mixed disulfide\\r\\nIn this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange. \\r\\nBecause CUPRIMINE can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids, should be used, when indicated, in conjunction with CUPRIMINE (see \\r\\nPRECAUTIONS</td>\n",
       "      <td>897</td>\n",
       "      <td>DB00859</td>\n",
       "      <td>Penicillamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>f0e16cc6-966d-4e3c-99c9-29a45d3480dc.xml</td>\n",
       "      <td>80e736d3-2017-4d68-94b4-38255c3c59c6</td>\n",
       "      <td>Cuprimine</td>\n",
       "      <td>Penicillamine</td>\n",
       "      <td>GNN1DV99GX</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>Except for the treatment of Wilson's disease or certain patients with cystinuria, use of penicillamine during pregnancy is contraindicated (see \\r\\nWARNINGS\\r\\nAlthough breast milk studies have not been reported in animals or humans, mothers on therapy with penicillamine should not nurse their infants. \\r\\nPatients with a history of penicillamine-related aplastic anemia or agranulocytosis should not be restarted on penicillamine (see \\r\\nWARNINGS\\r\\nADVERSE REACTIONS\\r\\nBecause of its potential for causing renal damage, penicillamine should not be administered to rheumatoid arthritis patients with a history or other evidence of renal insufficiency.</td>\n",
       "      <td>89</td>\n",
       "      <td>DB00859</td>\n",
       "      <td>Penicillamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>b5024702-310b-4170-a820-86ba597c4894.xml</td>\n",
       "      <td>4ebb9704-6b9f-4b47-aac4-d54fe34f0b83</td>\n",
       "      <td>CEFOTAXIME</td>\n",
       "      <td>CEFOTAXIME</td>\n",
       "      <td>N2GI8B1GK7</td>\n",
       "      <td>Indications</td>\n",
       "      <td>Cefotaxime for Injection USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below.\\r\\n \\r\\n \\r\\nLower\\r\\nrespiratory\\r\\ntract\\r\\ninfections\\r\\nStreptococcus\\r\\npneumoniae\\r\\nDiplococcus\\r\\npneumoniae\\r\\nStreptococcus\\r\\npyogenes\\r\\nEnterococcus\\r\\nfaecalis\\r\\nStaphylococcus\\r\\naureus\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nHaemophilus\\r\\ninfluenzae\\r\\nHaemophilus\\r\\nparainfluenzae\\r\\nProteus\\r\\nmirabilis\\r\\nSerratia\\r\\nmarcescens\\r\\nEnterobacter\\r\\nProteus\\r\\nPseudomonas\\r\\nP.\\r\\naeruginosa\\r\\n \\r\\nGenitourinary\\r\\ninfections\\r\\nEnterococcus\\r\\nStaphylococcus\\r\\nepidermidis\\r\\nStaphylococcus\\r\\naureus\\r\\nCitrobacter\\r\\nEnterobacter\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nProteus\\r\\nmirabilis\\r\\nProteus\\r\\nvulgaris\\r\\nProvidencia\\r\\nstuartii\\r\\nMorganella\\r\\nmorganii*\\r\\nProvidencia\\r\\nrettgeri*\\r\\nSerratia\\r\\nmarcescens\\r\\nPseudomonas\\r\\nP.\\r\\naeruginosa\\r\\nNeisseria\\r\\ngonorrhoeae\\r\\n \\r\\nGynecologic\\r\\ninfections\\r\\nStaphylococcus\\r\\nepidermidis\\r\\nStreptococcus\\r\\nEnterococcus\\r\\nEnterobacter\\r\\nKlebsiella\\r\\nEscherichia\\r\\ncoli\\r\\nProteus\\r\\nmirabilis\\r\\nBacteroides\\r\\nBacteroides\\r\\nfragilis\\r\\nClostridium\\r\\nPeptostreptococcus\\r\\nPeptococcus\\r\\nFusobacterium\\r\\nF.\\r\\nnucleatum\\r\\nChlamydia\\r\\ntrachomatis\\r\\nC.\\r\\ntrachomatis\\r\\n \\r\\nBacteremia/Septicemia\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nSerratia\\r\\nmarcescens\\r\\nStaphylococcus\\r\\naureus\\r\\nStreptococcus\\r\\nS.\\r\\npneumonia\\r\\n \\r\\nSkin\\r\\nand\\r\\nskin\\r\\nstructure\\r\\ninfections\\r\\nStaphylococcus\\r\\naureus\\r\\nStaphylococcus\\r\\nepidermidis\\r\\nStreptococcus\\r\\npyogenes\\r\\nEnterococcus\\r\\nAcinetobacter\\r\\nEscherichia\\r\\ncoli\\r\\nCitrobacter\\r\\nC.\\r\\nfreundii\\r\\nEnterobacter\\r\\nKlebsiella\\r\\nProteus\\r\\nmirabilis\\r\\nProteus\\r\\nvulgaris\\r\\nMorganella\\r\\nmorganii\\r\\nProvidencia\\r\\nrettgeri*\\r\\nPseudomonas\\r\\nSerratia\\r\\nmarcescens\\r\\nBacteroides\\r\\nPeptostreptococcus*\\r\\nPeptococcus\\r\\n \\r\\nIntra-abdominal\\r\\ninfections\\r\\nStreptococcus\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nBacteroides\\r\\nPeptostreptococcus*\\r\\nPeptococcus*\\r\\nProteus\\r\\nmirabilis\\r\\nClostridium\\r\\n \\r\\nBone\\r\\nand/or\\r\\njoint\\r\\ninfections\\r\\nStaphylococcus\\r\\naureus\\r\\nStreptococcus\\r\\nS.\\r\\npyogenes\\r\\nPseudomonas\\r\\nP.\\r\\naeruginosa\\r\\nProteus\\r\\nmirabilis\\r\\n \\r\\nCentral\\r\\nnervous\\r\\nsystem\\r\\ninfections\\r\\nNeisseria\\r\\nmeningitidis\\r\\nHaemophilus\\r\\ninfluenzae\\r\\nStreptococcus\\r\\npneumoniae\\r\\nKlebsiella\\r\\npneumoniae*\\r\\nEscherichia\\r\\ncoli*.\\r\\n(*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. \\r\\nAlthough many strains of enterococci (e.g., \\r\\nS\\r\\nfaecalis\\r\\nPseudomonas\\r\\nin\\r\\nvitro\\r\\nSpecimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.\\r\\nIn certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection USP is used concomitantly with an aminoglycoside. \\r\\nThe administration of cefotaxime for injection USP preoperatively reduces the incidence of certain infections in patients undergoing surgical procedures (e.g., abdominal or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or potentially contaminated. \\r\\nIn patients undergoing cesarean section, intraoperative (after clamping the umbilical cord) and postoperative use of cefotaxime for injection USP may also reduce the incidence of certain postoperative infections. See \\r\\n \\r\\nDOSAGE AND ADMINISTRATION \\r\\nEffective use for elective surgery depends on the time of administration. To achieve effective tissue levels, cefotaxime for injection USP should be given 1/2 or 1 1/2 hours before surgery. See \\r\\n \\r\\nDOSAGE AND ADMINISTRATION \\r\\nFor patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as with a non-absorbable antibiotic (e.g., neomycin) is recommended. \\r\\nIf there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate therapy may be instituted. \\r\\nTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotaxime for injection USP and other antibacterial drugs, cefotaxime for injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</td>\n",
       "      <td>621</td>\n",
       "      <td>DB00493</td>\n",
       "      <td>Cefotaxime</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>b5024702-310b-4170-a820-86ba597c4894.xml</td>\n",
       "      <td>4ebb9704-6b9f-4b47-aac4-d54fe34f0b83</td>\n",
       "      <td>CEFOTAXIME</td>\n",
       "      <td>CEFOTAXIME</td>\n",
       "      <td>N2GI8B1GK7</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>Cefotaxime for injection is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, or the cephalosporin group of antibiotics.</td>\n",
       "      <td>20</td>\n",
       "      <td>DB00493</td>\n",
       "      <td>Cefotaxime</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>7a01ce57-930d-7b1f-e053-2991aa0a0d75.xml</td>\n",
       "      <td>9b2f311f-365d-44e8-95eb-65c8709f4851</td>\n",
       "      <td>ATORVASTATIN CALCIUM</td>\n",
       "      <td>ATORVASTATIN</td>\n",
       "      <td>A0JWA85V8F</td>\n",
       "      <td>Indications</td>\n",
       "      <td>Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.\\r\\nAtorvastatin calcium tablets are an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:\\r\\n \\r\\nReduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors ( \\r\\n1.1\\r\\nReduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors ( \\r\\n1.1\\r\\nReduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD ( \\r\\n1.1\\r\\nReduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( \\r\\n1.2\\r\\nReduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( \\r\\n1.2\\r\\nReduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( \\r\\n1.2\\r\\nReduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( \\r\\n1.2\\r\\n \\r\\nAtorvastatin calcium have not been studied in Fredrickson Types I and V dyslipidemias.\\r\\nIn adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to:\\r\\n \\r\\nReduce the risk of myocardial infarction\\r\\nReduce the risk of stroke\\r\\nReduce the risk for revascularization procedures and angina\\r\\nIn patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: \\r\\n \\r\\nReduce the risk of myocardial infarction\\r\\nReduce the risk of stroke \\r\\nIn patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: \\r\\n \\r\\nReduce the risk of non-fatal myocardial infarction\\r\\nReduce the risk of fatal and non-fatal stroke\\r\\nReduce the risk for revascularization procedures\\r\\nReduce the risk of hospitalization for CHF\\r\\nReduce the risk of angina \\r\\nAtorvastatin calcium tablets are indicated: \\r\\n \\r\\nAs an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( \\r\\nFredrickson\\r\\nAs an adjunct to diet for the treatment of patients with elevated serum TG levels ( \\r\\nFredrickson\\r\\nFor the treatment of patients with primary dysbetalipoproteinemia ( \\r\\nFredrickson\\r\\nTo reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; \\r\\nAs an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: \\r\\n \\r\\nLDL-C remains &gt;= 190 mg/dL or \\r\\nLDL-C remains &gt;= 160 mg/dL and: \\r\\n \\r\\nthere is a positive family history of premature cardiovascular disease or \\r\\ntwo or more other CVD risk factors are present in the pediatric patient\\r\\nAtorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( \\r\\nFredrickson</td>\n",
       "      <td>598</td>\n",
       "      <td>DB01076</td>\n",
       "      <td>Atorvastatin</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Label_ID  \\\n",
       "0  f0e16cc6-966d-4e3c-99c9-29a45d3480dc.xml   \n",
       "1  f0e16cc6-966d-4e3c-99c9-29a45d3480dc.xml   \n",
       "2  b5024702-310b-4170-a820-86ba597c4894.xml   \n",
       "3  b5024702-310b-4170-a820-86ba597c4894.xml   \n",
       "4  7a01ce57-930d-7b1f-e053-2991aa0a0d75.xml   \n",
       "\n",
       "                                 Set_ID       Drug_Brand_Name  \\\n",
       "0  80e736d3-2017-4d68-94b4-38255c3c59c6  Cuprimine              \n",
       "1  80e736d3-2017-4d68-94b4-38255c3c59c6  Cuprimine              \n",
       "2  4ebb9704-6b9f-4b47-aac4-d54fe34f0b83  CEFOTAXIME             \n",
       "3  4ebb9704-6b9f-4b47-aac4-d54fe34f0b83  CEFOTAXIME             \n",
       "4  9b2f311f-365d-44e8-95eb-65c8709f4851  ATORVASTATIN CALCIUM   \n",
       "\n",
       "  Active_ingredient     UNII_ID            Section  \\\n",
       "0  Penicillamine     GNN1DV99GX  Indications         \n",
       "1  Penicillamine     GNN1DV99GX  Contraindications   \n",
       "2  CEFOTAXIME        N2GI8B1GK7  Indications         \n",
       "3  CEFOTAXIME        N2GI8B1GK7  Contraindications   \n",
       "4  ATORVASTATIN      A0JWA85V8F  Indications         \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Text  \\\n",
       "0  CUPRIMINE is indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that CUPRIMINE is not of value in ankylosing spondylitis. \\r\\nWilson's disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal-recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. \\r\\nTwo types of patients require treatment for Wilson's disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. \\r\\nThe diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is less than 20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (greater than 250 mcg/g dry weight) or Kayser-Fleischer rings are present. \\r\\nTreatment has two objectives: \\r\\n \\r\\n \\r\\n(1)\\r\\n \\r\\n(2)\\r\\nThe first objective is attained by a daily diet that contains no more than 1 or 2 mg of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient's drinking water contains more than 0.1 mg/L of copper. \\r\\nFor the second objective, a copper chelating agent is used. \\r\\nIn symptomatic patients, this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. \\r\\nClinical experience to date suggests that life is prolonged with the above regimen. \\r\\nNoticeable improvement may not occur for 1 to 3 months. Occasionally, neurologic symptoms become worse during initiation of therapy with CUPRIMINE. Despite this, the drug should not be withdrawn. Temporary interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see \\r\\nWARNINGS\\r\\nTreatment of asymptomatic patients has been carried out for over 30 years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with CUPRIMINE is continued. \\r\\nCystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal-recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction. \\r\\nArginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities. \\r\\nCystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria. \\r\\nNormal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated.\\r\\nConventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine-specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see \\r\\nPRECAUTIONS\\r\\nWhen these measures are inadequate to control recurrent stone formation, CUPRIMINE may be used as additional therapy, and when patients refuse to adhere to conventional treatment, CUPRIMINE may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients. Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillamine-cysteine mixed disulfide as:\\r\\n \\r\\n \\r\\n \\r\\n \\r\\n \\r\\nCSSC + PS'\\r\\n \\r\\n \\r\\n \\r\\nCS' + CSSP\\r\\n \\r\\n \\r\\n \\r\\nPSSP + CS'\\r\\n \\r\\n \\r\\n \\r\\nPS' + CSSP\\r\\n \\r\\n \\r\\n \\r\\nCSSC + PSSP'\\r\\n \\r\\n \\r\\n \\r\\n2CSSP\\r\\n \\r\\n \\r\\n \\r\\nCSSC = cystine\\r\\n \\r\\n \\r\\n \\r\\nCS' = deprotonated cysteine\\r\\n \\r\\n \\r\\n \\r\\nPSSP = penicillamine disulfide\\r\\n \\r\\n \\r\\n \\r\\nPS' = deprotonated penicillamine sulfhydryl\\r\\n \\r\\n \\r\\n \\r\\nCSSP = penicillamine-cysteine mixed disulfide\\r\\nIn this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange. \\r\\nBecause CUPRIMINE can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids, should be used, when indicated, in conjunction with CUPRIMINE (see \\r\\nPRECAUTIONS   \n",
       "1  Except for the treatment of Wilson's disease or certain patients with cystinuria, use of penicillamine during pregnancy is contraindicated (see \\r\\nWARNINGS\\r\\nAlthough breast milk studies have not been reported in animals or humans, mothers on therapy with penicillamine should not nurse their infants. \\r\\nPatients with a history of penicillamine-related aplastic anemia or agranulocytosis should not be restarted on penicillamine (see \\r\\nWARNINGS\\r\\nADVERSE REACTIONS\\r\\nBecause of its potential for causing renal damage, penicillamine should not be administered to rheumatoid arthritis patients with a history or other evidence of renal insufficiency.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   \n",
       "2  Cefotaxime for Injection USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below.\\r\\n \\r\\n \\r\\nLower\\r\\nrespiratory\\r\\ntract\\r\\ninfections\\r\\nStreptococcus\\r\\npneumoniae\\r\\nDiplococcus\\r\\npneumoniae\\r\\nStreptococcus\\r\\npyogenes\\r\\nEnterococcus\\r\\nfaecalis\\r\\nStaphylococcus\\r\\naureus\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nHaemophilus\\r\\ninfluenzae\\r\\nHaemophilus\\r\\nparainfluenzae\\r\\nProteus\\r\\nmirabilis\\r\\nSerratia\\r\\nmarcescens\\r\\nEnterobacter\\r\\nProteus\\r\\nPseudomonas\\r\\nP.\\r\\naeruginosa\\r\\n \\r\\nGenitourinary\\r\\ninfections\\r\\nEnterococcus\\r\\nStaphylococcus\\r\\nepidermidis\\r\\nStaphylococcus\\r\\naureus\\r\\nCitrobacter\\r\\nEnterobacter\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nProteus\\r\\nmirabilis\\r\\nProteus\\r\\nvulgaris\\r\\nProvidencia\\r\\nstuartii\\r\\nMorganella\\r\\nmorganii*\\r\\nProvidencia\\r\\nrettgeri*\\r\\nSerratia\\r\\nmarcescens\\r\\nPseudomonas\\r\\nP.\\r\\naeruginosa\\r\\nNeisseria\\r\\ngonorrhoeae\\r\\n \\r\\nGynecologic\\r\\ninfections\\r\\nStaphylococcus\\r\\nepidermidis\\r\\nStreptococcus\\r\\nEnterococcus\\r\\nEnterobacter\\r\\nKlebsiella\\r\\nEscherichia\\r\\ncoli\\r\\nProteus\\r\\nmirabilis\\r\\nBacteroides\\r\\nBacteroides\\r\\nfragilis\\r\\nClostridium\\r\\nPeptostreptococcus\\r\\nPeptococcus\\r\\nFusobacterium\\r\\nF.\\r\\nnucleatum\\r\\nChlamydia\\r\\ntrachomatis\\r\\nC.\\r\\ntrachomatis\\r\\n \\r\\nBacteremia/Septicemia\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nSerratia\\r\\nmarcescens\\r\\nStaphylococcus\\r\\naureus\\r\\nStreptococcus\\r\\nS.\\r\\npneumonia\\r\\n \\r\\nSkin\\r\\nand\\r\\nskin\\r\\nstructure\\r\\ninfections\\r\\nStaphylococcus\\r\\naureus\\r\\nStaphylococcus\\r\\nepidermidis\\r\\nStreptococcus\\r\\npyogenes\\r\\nEnterococcus\\r\\nAcinetobacter\\r\\nEscherichia\\r\\ncoli\\r\\nCitrobacter\\r\\nC.\\r\\nfreundii\\r\\nEnterobacter\\r\\nKlebsiella\\r\\nProteus\\r\\nmirabilis\\r\\nProteus\\r\\nvulgaris\\r\\nMorganella\\r\\nmorganii\\r\\nProvidencia\\r\\nrettgeri*\\r\\nPseudomonas\\r\\nSerratia\\r\\nmarcescens\\r\\nBacteroides\\r\\nPeptostreptococcus*\\r\\nPeptococcus\\r\\n \\r\\nIntra-abdominal\\r\\ninfections\\r\\nStreptococcus\\r\\nEscherichia\\r\\ncoli\\r\\nKlebsiella\\r\\nBacteroides\\r\\nPeptostreptococcus*\\r\\nPeptococcus*\\r\\nProteus\\r\\nmirabilis\\r\\nClostridium\\r\\n \\r\\nBone\\r\\nand/or\\r\\njoint\\r\\ninfections\\r\\nStaphylococcus\\r\\naureus\\r\\nStreptococcus\\r\\nS.\\r\\npyogenes\\r\\nPseudomonas\\r\\nP.\\r\\naeruginosa\\r\\nProteus\\r\\nmirabilis\\r\\n \\r\\nCentral\\r\\nnervous\\r\\nsystem\\r\\ninfections\\r\\nNeisseria\\r\\nmeningitidis\\r\\nHaemophilus\\r\\ninfluenzae\\r\\nStreptococcus\\r\\npneumoniae\\r\\nKlebsiella\\r\\npneumoniae*\\r\\nEscherichia\\r\\ncoli*.\\r\\n(*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. \\r\\nAlthough many strains of enterococci (e.g., \\r\\nS\\r\\nfaecalis\\r\\nPseudomonas\\r\\nin\\r\\nvitro\\r\\nSpecimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly.\\r\\nIn certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection USP is used concomitantly with an aminoglycoside. \\r\\nThe administration of cefotaxime for injection USP preoperatively reduces the incidence of certain infections in patients undergoing surgical procedures (e.g., abdominal or vaginal hysterectomy, gastrointestinal and genitourinary tract surgery) that may be classified as contaminated or potentially contaminated. \\r\\nIn patients undergoing cesarean section, intraoperative (after clamping the umbilical cord) and postoperative use of cefotaxime for injection USP may also reduce the incidence of certain postoperative infections. See \\r\\n \\r\\nDOSAGE AND ADMINISTRATION \\r\\nEffective use for elective surgery depends on the time of administration. To achieve effective tissue levels, cefotaxime for injection USP should be given 1/2 or 1 1/2 hours before surgery. See \\r\\n \\r\\nDOSAGE AND ADMINISTRATION \\r\\nFor patients undergoing gastrointestinal surgery, preoperative bowel preparation by mechanical cleansing as well as with a non-absorbable antibiotic (e.g., neomycin) is recommended. \\r\\nIf there are signs of infection, specimens for culture should be obtained for identification of the causative organism so that appropriate therapy may be instituted. \\r\\nTo reduce the development of drug-resistant bacteria and maintain the effectiveness of cefotaxime for injection USP and other antibacterial drugs, cefotaxime for injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \n",
       "3  Cefotaxime for injection is contraindicated in patients who have shown hypersensitivity to cefotaxime sodium, or the cephalosporin group of antibiotics.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           \n",
       "4  Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet.\\r\\nAtorvastatin calcium tablets are an inhibitor of HMG-CoA reductase (statin) indicated as an adjunct therapy to diet to:\\r\\n \\r\\nReduce the risk of MI, stroke, revascularization procedures, and angina in patients without CHD, but with multiple risk factors ( \\r\\n1.1\\r\\nReduce the risk of MI and stroke in patients with type 2 diabetes without CHD, but with multiple risk factors ( \\r\\n1.1\\r\\nReduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in patients with CHD ( \\r\\n1.1\\r\\nReduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( \\r\\n1.2\\r\\nReduce elevated TG in patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( \\r\\n1.2\\r\\nReduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( \\r\\n1.2\\r\\nReduce elevated total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy ( \\r\\n1.2\\r\\n \\r\\nAtorvastatin calcium have not been studied in Fredrickson Types I and V dyslipidemias.\\r\\nIn adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to:\\r\\n \\r\\nReduce the risk of myocardial infarction\\r\\nReduce the risk of stroke\\r\\nReduce the risk for revascularization procedures and angina\\r\\nIn patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: \\r\\n \\r\\nReduce the risk of myocardial infarction\\r\\nReduce the risk of stroke \\r\\nIn patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: \\r\\n \\r\\nReduce the risk of non-fatal myocardial infarction\\r\\nReduce the risk of fatal and non-fatal stroke\\r\\nReduce the risk for revascularization procedures\\r\\nReduce the risk of hospitalization for CHF\\r\\nReduce the risk of angina \\r\\nAtorvastatin calcium tablets are indicated: \\r\\n \\r\\nAs an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( \\r\\nFredrickson\\r\\nAs an adjunct to diet for the treatment of patients with elevated serum TG levels ( \\r\\nFredrickson\\r\\nFor the treatment of patients with primary dysbetalipoproteinemia ( \\r\\nFredrickson\\r\\nTo reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; \\r\\nAs an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: \\r\\n \\r\\nLDL-C remains >= 190 mg/dL or \\r\\nLDL-C remains >= 160 mg/dL and: \\r\\n \\r\\nthere is a positive family history of premature cardiovascular disease or \\r\\ntwo or more other CVD risk factors are present in the pediatric patient\\r\\nAtorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( \\r\\nFredrickson                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         \n",
       "\n",
       "   WordCount    DB_ID      Drug_name  \n",
       "0  897        DB00859  Penicillamine  \n",
       "1  89         DB00859  Penicillamine  \n",
       "2  621        DB00493  Cefotaxime     \n",
       "3  20         DB00493  Cefotaxime     \n",
       "4  598        DB01076  Atorvastatin   "
      ]
     },
     "execution_count": 53,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "xml_df = pd.read_csv('/jupyter/output/XMLProduct_DBID.csv')\n",
    "xml_df.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 56,
   "metadata": {},
   "outputs": [],
   "source": [
    "xml_df.rename(columns={'Text':'Context'}, inplace=True)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 61,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>From</th>\n",
       "      <th>To</th>\n",
       "      <th>Type</th>\n",
       "      <th>Annotation</th>\n",
       "      <th>Context</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DrugName</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>63</td>\n",
       "      <td>78</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>516</td>\n",
       "      <td>531</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml</td>\n",
       "      <td>608</td>\n",
       "      <td>623</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml</td>\n",
       "      <td>63</td>\n",
       "      <td>78</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml</td>\n",
       "      <td>516</td>\n",
       "      <td>531</td>\n",
       "      <td>SYN</td>\n",
       "      <td>HYPERSENSITIVITY</td>\n",
       "      <td>OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.</td>\n",
       "      <td>http://purl.obolibrary.org/obo/DOID_1205</td>\n",
       "      <td>DB01362</td>\n",
       "      <td>Iohexol</td>\n",
       "      <td>Omnipaque</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Label_ID  From   To Type        Annotation  \\\n",
       "0  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml  63    78   SYN  HYPERSENSITIVITY   \n",
       "1  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml  516   531  SYN  HYPERSENSITIVITY   \n",
       "2  9fb5dedd-b589-42b7-850a-41dfc5bd8688.xml  608   623  SYN  HYPERSENSITIVITY   \n",
       "3  2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml  63    78   SYN  HYPERSENSITIVITY   \n",
       "4  2e8a4140-97a5-4031-a6df-4b2663b5bf83.xml  516   531  SYN  HYPERSENSITIVITY   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     Context  \\\n",
       "0  OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.   \n",
       "1  OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.   \n",
       "2  OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.   \n",
       "3  OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.   \n",
       "4  OMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol. Myelography should not be performed in the presence of significant local or systemic infection where bacteremia is likely. Intrathecal administration of corticosteroids with OMNIPAQUE is contraindicated. Because of the possibility of overdosage, immediate repeat myelography in the event of technical failure is contraindicated (see \\r\\nDOSAGE AND ADMINISTRATION\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nOMNIPAQUE should not be administered to patients with a known hypersensitivity to iohexol.\\r\\nThe procedure should not be performed during the menstrual period or when menstrual flow is imminent, nor should it be performed when infection is present in any portion of the genital tract, including the external genitalia. The procedure is also contraindicated for pregnant women or for those in whom pregnancy is suspected. Its use is not advised for 6 months after termination of pregnancy or 30 days after conization or curettage.   \n",
       "\n",
       "                                      DO_ID    DB_ID DrugName Drug_Brand_Name  \n",
       "0  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol  Omnipaque       \n",
       "1  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol  Omnipaque       \n",
       "2  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol  Omnipaque       \n",
       "3  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol  Omnipaque       \n",
       "4  http://purl.obolibrary.org/obo/DOID_1205  DB01362  Iohexol  Omnipaque       "
      ]
     },
     "execution_count": 61,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "unlabelled = pd.read_csv('/data/output/XMLProduct_annotations.csv')\n",
    "unlabelled.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 62,
   "metadata": {},
   "outputs": [],
   "source": [
    "unlabelled =unlabelled.merge(xml_df, on=['Label_ID','Context','Drug_Brand_Name','DB_ID'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 67,
   "metadata": {},
   "outputs": [],
   "source": [
    "unlabelled.DO_ID = unlabelled.DO_ID.str.replace('http://purl.obolibrary.org/obo/','')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 73,
   "metadata": {},
   "outputs": [],
   "source": [
    "unlabelled= unlabelled.drop_duplicates(subset=['Context','DO_ID'], keep='first')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 74,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>From</th>\n",
       "      <th>To</th>\n",
       "      <th>Type</th>\n",
       "      <th>Annotation</th>\n",
       "      <th>Context</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DrugName</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "      <th>Set_ID</th>\n",
       "      <th>Active_ingredient</th>\n",
       "      <th>UNII_ID</th>\n",
       "      <th>Section</th>\n",
       "      <th>WordCount</th>\n",
       "      <th>Drug_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>50bfe7b3-bfda-068b-e054-00144ff8d46c.xml</td>\n",
       "      <td>58</td>\n",
       "      <td>64</td>\n",
       "      <td>SYN</td>\n",
       "      <td>ANXIETY</td>\n",
       "      <td>Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.</td>\n",
       "      <td>DOID_2030</td>\n",
       "      <td>DB00829</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>50bfe7b3-bfd9-068b-e054-00144ff8d46c</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>Q3JTX2Q7TU</td>\n",
       "      <td>Indications</td>\n",
       "      <td>164</td>\n",
       "      <td>Diazepam</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>50bfe7b3-bfda-068b-e054-00144ff8d46c.xml</td>\n",
       "      <td>377</td>\n",
       "      <td>392</td>\n",
       "      <td>SYN</td>\n",
       "      <td>DELIRIUM TREMENS</td>\n",
       "      <td>Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.</td>\n",
       "      <td>DOID_8639</td>\n",
       "      <td>DB00829</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>50bfe7b3-bfd9-068b-e054-00144ff8d46c</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>Q3JTX2Q7TU</td>\n",
       "      <td>Indications</td>\n",
       "      <td>164</td>\n",
       "      <td>Diazepam</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>50bfe7b3-bfda-068b-e054-00144ff8d46c.xml</td>\n",
       "      <td>653</td>\n",
       "      <td>666</td>\n",
       "      <td>PREF</td>\n",
       "      <td>CEREBRAL PALSY</td>\n",
       "      <td>Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.</td>\n",
       "      <td>DOID_1969</td>\n",
       "      <td>DB00829</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>50bfe7b3-bfd9-068b-e054-00144ff8d46c</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>Q3JTX2Q7TU</td>\n",
       "      <td>Indications</td>\n",
       "      <td>164</td>\n",
       "      <td>Diazepam</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>5</th>\n",
       "      <td>50bfe7b3-bfda-068b-e054-00144ff8d46c.xml</td>\n",
       "      <td>672</td>\n",
       "      <td>681</td>\n",
       "      <td>PREF</td>\n",
       "      <td>PARAPLEGIA</td>\n",
       "      <td>Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.</td>\n",
       "      <td>DOID_607</td>\n",
       "      <td>DB00829</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>50bfe7b3-bfd9-068b-e054-00144ff8d46c</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>Q3JTX2Q7TU</td>\n",
       "      <td>Indications</td>\n",
       "      <td>164</td>\n",
       "      <td>Diazepam</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>6</th>\n",
       "      <td>50bfe7b3-bfda-068b-e054-00144ff8d46c.xml</td>\n",
       "      <td>700</td>\n",
       "      <td>717</td>\n",
       "      <td>SYN</td>\n",
       "      <td>STIFF-MAN SYNDROME</td>\n",
       "      <td>Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.</td>\n",
       "      <td>DOID_13366</td>\n",
       "      <td>DB00829</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>50bfe7b3-bfd9-068b-e054-00144ff8d46c</td>\n",
       "      <td>DIAZEPAM</td>\n",
       "      <td>Q3JTX2Q7TU</td>\n",
       "      <td>Indications</td>\n",
       "      <td>164</td>\n",
       "      <td>Diazepam</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "</div>"
      ],
      "text/plain": [
       "                                   Label_ID  From   To  Type  \\\n",
       "0  50bfe7b3-bfda-068b-e054-00144ff8d46c.xml  58    64   SYN    \n",
       "3  50bfe7b3-bfda-068b-e054-00144ff8d46c.xml  377   392  SYN    \n",
       "4  50bfe7b3-bfda-068b-e054-00144ff8d46c.xml  653   666  PREF   \n",
       "5  50bfe7b3-bfda-068b-e054-00144ff8d46c.xml  672   681  PREF   \n",
       "6  50bfe7b3-bfda-068b-e054-00144ff8d46c.xml  700   717  SYN    \n",
       "\n",
       "           Annotation  \\\n",
       "0  ANXIETY              \n",
       "3  DELIRIUM TREMENS     \n",
       "4  CEREBRAL PALSY       \n",
       "5  PARAPLEGIA           \n",
       "6  STIFF-MAN SYNDROME   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                Context  \\\n",
       "0  Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.   \n",
       "3  Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.   \n",
       "4  Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.   \n",
       "5  Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.   \n",
       "6  Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic.\\r\\nIn acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis.\\r\\nDiazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome.\\r\\nOral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy.\\r\\nThe effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient.   \n",
       "\n",
       "        DO_ID    DB_ID  DrugName Drug_Brand_Name  \\\n",
       "0  DOID_2030   DB00829  DIAZEPAM  DIAZEPAM         \n",
       "3  DOID_8639   DB00829  DIAZEPAM  DIAZEPAM         \n",
       "4  DOID_1969   DB00829  DIAZEPAM  DIAZEPAM         \n",
       "5  DOID_607    DB00829  DIAZEPAM  DIAZEPAM         \n",
       "6  DOID_13366  DB00829  DIAZEPAM  DIAZEPAM         \n",
       "\n",
       "                                 Set_ID Active_ingredient     UNII_ID  \\\n",
       "0  50bfe7b3-bfd9-068b-e054-00144ff8d46c  DIAZEPAM          Q3JTX2Q7TU   \n",
       "3  50bfe7b3-bfd9-068b-e054-00144ff8d46c  DIAZEPAM          Q3JTX2Q7TU   \n",
       "4  50bfe7b3-bfd9-068b-e054-00144ff8d46c  DIAZEPAM          Q3JTX2Q7TU   \n",
       "5  50bfe7b3-bfd9-068b-e054-00144ff8d46c  DIAZEPAM          Q3JTX2Q7TU   \n",
       "6  50bfe7b3-bfd9-068b-e054-00144ff8d46c  DIAZEPAM          Q3JTX2Q7TU   \n",
       "\n",
       "       Section  WordCount Drug_name  \n",
       "0  Indications  164        Diazepam  \n",
       "3  Indications  164        Diazepam  \n",
       "4  Indications  164        Diazepam  \n",
       "5  Indications  164        Diazepam  \n",
       "6  Indications  164        Diazepam  "
      ]
     },
     "execution_count": 74,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "unlabelled.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 75,
   "metadata": {},
   "outputs": [],
   "source": [
    "match2 = missing.merge(unlabelled, on=['DB_ID','DO_ID','Label_ID','Section'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 76,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>disease</th>\n",
       "      <th>drug</th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>relation</th>\n",
       "      <th>text</th>\n",
       "      <th>Section</th>\n",
       "      <th>From</th>\n",
       "      <th>...</th>\n",
       "      <th>Type</th>\n",
       "      <th>Annotation</th>\n",
       "      <th>Context</th>\n",
       "      <th>DrugName</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "      <th>Set_ID</th>\n",
       "      <th>Active_ingredient</th>\n",
       "      <th>UNII_ID</th>\n",
       "      <th>WordCount</th>\n",
       "      <th>Drug_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>219</th>\n",
       "      <td>3175</td>\n",
       "      <td>DB00541</td>\n",
       "      <td>DOID_225</td>\n",
       "      <td>syndrome</td>\n",
       "      <td>Vincristine</td>\n",
       "      <td>768cd59b-38a2-4af5-ab91-4d46ae808ab3.xml</td>\n",
       "      <td>IDK</td>\n",
       "      <td>Marqibo is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.\\nMarqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of Marqibo (vinCRIStine sulfate LIPOSOME injection).\\nMarqibo is contraindicated for intrathecal administration.\\n\\n\\n\\n\\n\\n4\\n\\n\\n\\n4\\n\\n\\n\\n4</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>100</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>SYNDROME</td>\n",
       "      <td>Marqibo is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.\\r\\nMarqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of Marqibo (vinCRIStine sulfate LIPOSOME injection).\\r\\nMarqibo is contraindicated for intrathecal administration.\\r\\n \\r\\n \\r\\n*\\r\\n4\\r\\n \\r\\n*\\r\\n4\\r\\n \\r\\n*\\r\\n4</td>\n",
       "      <td>Vincristine</td>\n",
       "      <td>Marqibo</td>\n",
       "      <td>a1869e23-b93b-4407-843b-4b830319d82e</td>\n",
       "      <td>Vincristine</td>\n",
       "      <td>5J49Q6B70F</td>\n",
       "      <td>45</td>\n",
       "      <td>Vincristine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>220</th>\n",
       "      <td>3211</td>\n",
       "      <td>DB00746</td>\n",
       "      <td>DOID_2983</td>\n",
       "      <td>anuria</td>\n",
       "      <td>Deferoxamine</td>\n",
       "      <td>61f30881-2af7-4103-b9ce-d9dc745159fe.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Known hypersensitivity to the active substance.\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see\\n\\n\\nWARNINGS</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>132</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>ANURIA</td>\n",
       "      <td>Known hypersensitivity to the active substance.\\r\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see \\r\\n \\r\\nWARNINGS</td>\n",
       "      <td>DEFEROXAMINE</td>\n",
       "      <td>Deferoxamine Mesylate</td>\n",
       "      <td>f9ab6b1c-98d0-4373-0e9b-b10cb4a67543</td>\n",
       "      <td>DEFEROXAMINE</td>\n",
       "      <td>J06Y7MXW4D</td>\n",
       "      <td>33</td>\n",
       "      <td>Deferoxamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>221</th>\n",
       "      <td>3263</td>\n",
       "      <td>DB00746</td>\n",
       "      <td>DOID_4</td>\n",
       "      <td>disease</td>\n",
       "      <td>Deferoxamine</td>\n",
       "      <td>61f30881-2af7-4103-b9ce-d9dc745159fe.xml</td>\n",
       "      <td>IDK</td>\n",
       "      <td>Known hypersensitivity to the active substance.\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see\\n\\n\\nWARNINGS</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>121</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>DISEASE</td>\n",
       "      <td>Known hypersensitivity to the active substance.\\r\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see \\r\\n \\r\\nWARNINGS</td>\n",
       "      <td>DEFEROXAMINE</td>\n",
       "      <td>Deferoxamine Mesylate</td>\n",
       "      <td>f9ab6b1c-98d0-4373-0e9b-b10cb4a67543</td>\n",
       "      <td>DEFEROXAMINE</td>\n",
       "      <td>J06Y7MXW4D</td>\n",
       "      <td>33</td>\n",
       "      <td>Deferoxamine</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>222</th>\n",
       "      <td>3323</td>\n",
       "      <td>DB01032</td>\n",
       "      <td>DOID_585</td>\n",
       "      <td>nephrolithiasis</td>\n",
       "      <td>Probenecid</td>\n",
       "      <td>38a2d4c1-e32a-2dbb-e054-00144ff8d46c.xml</td>\n",
       "      <td>relief</td>\n",
       "      <td>['Hypersensitivity to probenecid.', None, 'Children under 2 years of age.', None, 'Not recommended in persons with known blood dyscrasias or uric acid kidney stones.', None, 'Therapy with probenecid should not be started until an acute gouty attack has subsided.']</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>134</td>\n",
       "      <td>...</td>\n",
       "      <td>SYN</td>\n",
       "      <td>KIDNEY STONES</td>\n",
       "      <td>Hypersensitivity to probenecid.\\r\\nChildren under 2 years of age.\\r\\nNot recommended in persons with known blood dyscrasias or uric acid kidney stones.\\r\\nTherapy with probenecid should not be started until an acute gouty attack has subsided.</td>\n",
       "      <td>PROBENECID</td>\n",
       "      <td>Probenecid</td>\n",
       "      <td>38a2d4c1-e329-2dbb-e054-00144ff8d46c</td>\n",
       "      <td>PROBENECID</td>\n",
       "      <td>PO572Z7917</td>\n",
       "      <td>36</td>\n",
       "      <td>Probenecid</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>223</th>\n",
       "      <td>3373</td>\n",
       "      <td>DB01421</td>\n",
       "      <td>DOID_8437</td>\n",
       "      <td>intestinal obstruction</td>\n",
       "      <td>Paromomycin</td>\n",
       "      <td>2b5b3dae-b407-1e2e-e054-00144ff88e88.xml</td>\n",
       "      <td>contraindication</td>\n",
       "      <td>Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.</td>\n",
       "      <td>Contraindications</td>\n",
       "      <td>146</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>INTESTINAL OBSTRUCTION</td>\n",
       "      <td>Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.</td>\n",
       "      <td>PAROMOMYCIN</td>\n",
       "      <td>Paromomycin Sulfate</td>\n",
       "      <td>2b5b3dae-b406-1e2e-e054-00144ff88e88</td>\n",
       "      <td>PAROMOMYCIN</td>\n",
       "      <td>61JJC8N5ZK</td>\n",
       "      <td>22</td>\n",
       "      <td>Paromomycin</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "     Unnamed: 0    DB_ID      DO_ID                 disease          drug  \\\n",
       "219  3175        DB00541  DOID_225   syndrome                Vincristine    \n",
       "220  3211        DB00746  DOID_2983  anuria                  Deferoxamine   \n",
       "221  3263        DB00746  DOID_4     disease                 Deferoxamine   \n",
       "222  3323        DB01032  DOID_585   nephrolithiasis         Probenecid     \n",
       "223  3373        DB01421  DOID_8437  intestinal obstruction  Paromomycin    \n",
       "\n",
       "                                     Label_ID          relation  \\\n",
       "219  768cd59b-38a2-4af5-ab91-4d46ae808ab3.xml  IDK                \n",
       "220  61f30881-2af7-4103-b9ce-d9dc745159fe.xml  treatment          \n",
       "221  61f30881-2af7-4103-b9ce-d9dc745159fe.xml  IDK                \n",
       "222  38a2d4c1-e32a-2dbb-e054-00144ff8d46c.xml  relief             \n",
       "223  2b5b3dae-b407-1e2e-e054-00144ff88e88.xml  contraindication   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                 text  \\\n",
       "219  Marqibo is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.\\nMarqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of Marqibo (vinCRIStine sulfate LIPOSOME injection).\\nMarqibo is contraindicated for intrathecal administration.\\n\\n\\n\\n\\n\\n4\\n\\n\\n\\n4\\n\\n\\n\\n4   \n",
       "220  Known hypersensitivity to the active substance.\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see\\n\\n\\nWARNINGS                                                                                                                                                                                             \n",
       "221  Known hypersensitivity to the active substance.\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see\\n\\n\\nWARNINGS                                                                                                                                                                                             \n",
       "222  ['Hypersensitivity to probenecid.', None, 'Children under 2 years of age.', None, 'Not recommended in persons with known blood dyscrasias or uric acid kidney stones.', None, 'Therapy with probenecid should not be started until an acute gouty attack has subsided.']                                                                                                                                                           \n",
       "223  Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.                                                                                                                                                                                                                                                           \n",
       "\n",
       "               Section  From  ...  Type              Annotation  \\\n",
       "219  Contraindications  100   ...  PREF  SYNDROME                 \n",
       "220  Contraindications  132   ...  PREF  ANURIA                   \n",
       "221  Contraindications  121   ...  PREF  DISEASE                  \n",
       "222  Contraindications  134   ...  SYN   KIDNEY STONES            \n",
       "223  Contraindications  146   ...  PREF  INTESTINAL OBSTRUCTION   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                     Context  \\\n",
       "219  Marqibo is contraindicated in patients with demyelinating conditions including Charcot-Marie-Tooth syndrome.\\r\\nMarqibo is contraindicated in patients with hypersensitivity to vincristine sulfate or any of the other components of Marqibo (vinCRIStine sulfate LIPOSOME injection).\\r\\nMarqibo is contraindicated for intrathecal administration.\\r\\n \\r\\n \\r\\n*\\r\\n4\\r\\n \\r\\n*\\r\\n4\\r\\n \\r\\n*\\r\\n4   \n",
       "220  Known hypersensitivity to the active substance.\\r\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see \\r\\n \\r\\nWARNINGS                                                                                                                                                              \n",
       "221  Known hypersensitivity to the active substance.\\r\\nDeferoxamine mesylate is contraindicated in patients with severe renal disease or anuria, since the drug and the iron chelate are excreted primarily by the kidney (see \\r\\n \\r\\nWARNINGS                                                                                                                                                              \n",
       "222  Hypersensitivity to probenecid.\\r\\nChildren under 2 years of age.\\r\\nNot recommended in persons with known blood dyscrasias or uric acid kidney stones.\\r\\nTherapy with probenecid should not be started until an acute gouty attack has subsided.                                                                                                                                                        \n",
       "223  Paromomycin sulfate is contraindicated in individuals with a history of previous hypersensitivity reactions to it. It is also contraindicated in intestinal obstruction.                                                                                                                                                                                                                                  \n",
       "\n",
       "         DrugName        Drug_Brand_Name  \\\n",
       "219  Vincristine   Marqibo                 \n",
       "220  DEFEROXAMINE  Deferoxamine Mesylate   \n",
       "221  DEFEROXAMINE  Deferoxamine Mesylate   \n",
       "222  PROBENECID    Probenecid              \n",
       "223  PAROMOMYCIN   Paromomycin Sulfate     \n",
       "\n",
       "                                   Set_ID Active_ingredient     UNII_ID  \\\n",
       "219  a1869e23-b93b-4407-843b-4b830319d82e  Vincristine       5J49Q6B70F   \n",
       "220  f9ab6b1c-98d0-4373-0e9b-b10cb4a67543  DEFEROXAMINE      J06Y7MXW4D   \n",
       "221  f9ab6b1c-98d0-4373-0e9b-b10cb4a67543  DEFEROXAMINE      J06Y7MXW4D   \n",
       "222  38a2d4c1-e329-2dbb-e054-00144ff8d46c  PROBENECID        PO572Z7917   \n",
       "223  2b5b3dae-b406-1e2e-e054-00144ff88e88  PAROMOMYCIN       61JJC8N5ZK   \n",
       "\n",
       "    WordCount     Drug_name  \n",
       "219  45        Vincristine   \n",
       "220  33        Deferoxamine  \n",
       "221  33        Deferoxamine  \n",
       "222  36        Probenecid    \n",
       "223  22        Paromomycin   \n",
       "\n",
       "[5 rows x 21 columns]"
      ]
     },
     "execution_count": 76,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "match2.tail()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 77,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "224"
      ]
     },
     "execution_count": 77,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "len(match2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 82,
   "metadata": {},
   "outputs": [],
   "source": [
    "#match1 = match.drop(columns=['drug','disease'])"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 78,
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "/home/jovyan/.local/lib/python3.7/site-packages/pandas/core/frame.py:7138: FutureWarning: Sorting because non-concatenation axis is not aligned. A future version\n",
      "of pandas will change to not sort by default.\n",
      "\n",
      "To accept the future behavior, pass 'sort=False'.\n",
      "\n",
      "To retain the current behavior and silence the warning, pass 'sort=True'.\n",
      "\n",
      "  sort=sort,\n"
     ]
    }
   ],
   "source": [
    "match_all = match.append(match2)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 80,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/html": [
       "<div>\n",
       "<style scoped>\n",
       "    .dataframe tbody tr th:only-of-type {\n",
       "        vertical-align: middle;\n",
       "    }\n",
       "\n",
       "    .dataframe tbody tr th {\n",
       "        vertical-align: top;\n",
       "    }\n",
       "\n",
       "    .dataframe thead th {\n",
       "        text-align: right;\n",
       "    }\n",
       "</style>\n",
       "<table border=\"1\" class=\"dataframe\">\n",
       "  <thead>\n",
       "    <tr style=\"text-align: right;\">\n",
       "      <th></th>\n",
       "      <th>Unnamed: 0</th>\n",
       "      <th>DB_ID</th>\n",
       "      <th>DO_ID</th>\n",
       "      <th>disease</th>\n",
       "      <th>drug</th>\n",
       "      <th>Label_ID</th>\n",
       "      <th>relation</th>\n",
       "      <th>text</th>\n",
       "      <th>Section</th>\n",
       "      <th>From</th>\n",
       "      <th>...</th>\n",
       "      <th>Type</th>\n",
       "      <th>Annotation</th>\n",
       "      <th>Context</th>\n",
       "      <th>DrugName</th>\n",
       "      <th>Drug_Brand_Name</th>\n",
       "      <th>Set_ID</th>\n",
       "      <th>Active_ingredient</th>\n",
       "      <th>UNII_ID</th>\n",
       "      <th>WordCount</th>\n",
       "      <th>Drug_name</th>\n",
       "    </tr>\n",
       "  </thead>\n",
       "  <tbody>\n",
       "    <tr>\n",
       "      <th>0</th>\n",
       "      <td>10</td>\n",
       "      <td>DB00350</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Minoxidil</td>\n",
       "      <td>66cce4de-c6bc-42f8-9fdf-6c9814f58152.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75 of patients, most of who had hypertension that could not be controlled by other drugs.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>112</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\r\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.</td>\n",
       "      <td>minoxidil</td>\n",
       "      <td>MINOXIDIL</td>\n",
       "      <td>032835ab-1c8b-418a-9009-b6ebe58676dc</td>\n",
       "      <td>minoxidil</td>\n",
       "      <td>5965120SH1</td>\n",
       "      <td>102</td>\n",
       "      <td>Minoxidil</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>1</th>\n",
       "      <td>442</td>\n",
       "      <td>DB00350</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Minoxidil</td>\n",
       "      <td>66cce4de-c6bc-42f8-9fdf-6c9814f58152.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>112</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\r\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.</td>\n",
       "      <td>minoxidil</td>\n",
       "      <td>MINOXIDIL</td>\n",
       "      <td>032835ab-1c8b-418a-9009-b6ebe58676dc</td>\n",
       "      <td>minoxidil</td>\n",
       "      <td>5965120SH1</td>\n",
       "      <td>102</td>\n",
       "      <td>Minoxidil</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>2</th>\n",
       "      <td>1270</td>\n",
       "      <td>DB00350</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>drug</td>\n",
       "      <td>66cce4de-c6bc-42f8-9fdf-6c9814f58152.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>112</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\r\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.</td>\n",
       "      <td>minoxidil</td>\n",
       "      <td>MINOXIDIL</td>\n",
       "      <td>032835ab-1c8b-418a-9009-b6ebe58676dc</td>\n",
       "      <td>minoxidil</td>\n",
       "      <td>5965120SH1</td>\n",
       "      <td>102</td>\n",
       "      <td>Minoxidil</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>3</th>\n",
       "      <td>11</td>\n",
       "      <td>DB00542</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Benazepril</td>\n",
       "      <td>8fdc8bda-635a-401f-a9b5-8a2a514b429e.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>74</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics.\\r\\nIn using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS).\\r\\nBlack patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.</td>\n",
       "      <td>BENAZEPRIL</td>\n",
       "      <td>Benazepril Hydrochloride</td>\n",
       "      <td>8fdc8bda-635a-401f-a9b5-8a2a514b429e</td>\n",
       "      <td>BENAZEPRIL</td>\n",
       "      <td>UDM7Q7QWP8</td>\n",
       "      <td>115</td>\n",
       "      <td>Benazepril</td>\n",
       "    </tr>\n",
       "    <tr>\n",
       "      <th>4</th>\n",
       "      <td>443</td>\n",
       "      <td>DB00542</td>\n",
       "      <td>DOID_10763</td>\n",
       "      <td>hypertension</td>\n",
       "      <td>Benazepril</td>\n",
       "      <td>8fdc8bda-635a-401f-a9b5-8a2a514b429e.xml</td>\n",
       "      <td>treatment</td>\n",
       "      <td>Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics.\\nIn using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS).\\nBlack patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.</td>\n",
       "      <td>Indications</td>\n",
       "      <td>74</td>\n",
       "      <td>...</td>\n",
       "      <td>PREF</td>\n",
       "      <td>HYPERTENSION</td>\n",
       "      <td>Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics.\\r\\nIn using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS).\\r\\nBlack patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.</td>\n",
       "      <td>BENAZEPRIL</td>\n",
       "      <td>Benazepril Hydrochloride</td>\n",
       "      <td>8fdc8bda-635a-401f-a9b5-8a2a514b429e</td>\n",
       "      <td>BENAZEPRIL</td>\n",
       "      <td>UDM7Q7QWP8</td>\n",
       "      <td>115</td>\n",
       "      <td>Benazepril</td>\n",
       "    </tr>\n",
       "  </tbody>\n",
       "</table>\n",
       "<p>5 rows  21 columns</p>\n",
       "</div>"
      ],
      "text/plain": [
       "   Unnamed: 0    DB_ID       DO_ID       disease        drug  \\\n",
       "0  10          DB00350  DOID_10763  hypertension  Minoxidil    \n",
       "1  442         DB00350  DOID_10763  hypertension  Minoxidil    \n",
       "2  1270        DB00350  DOID_10763  hypertension  drug         \n",
       "3  11          DB00542  DOID_10763  hypertension  Benazepril   \n",
       "4  443         DB00542  DOID_10763  hypertension  Benazepril   \n",
       "\n",
       "                                   Label_ID   relation  \\\n",
       "0  66cce4de-c6bc-42f8-9fdf-6c9814f58152.xml  treatment   \n",
       "1  66cce4de-c6bc-42f8-9fdf-6c9814f58152.xml  treatment   \n",
       "2  66cce4de-c6bc-42f8-9fdf-6c9814f58152.xml  treatment   \n",
       "3  8fdc8bda-635a-401f-a9b5-8a2a514b429e.xml  treatment   \n",
       "4  8fdc8bda-635a-401f-a9b5-8a2a514b429e.xml  treatment   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              text  \\\n",
       "0  Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75 of patients, most of who had hypertension that could not be controlled by other drugs.                                                                                                                                                                                        \n",
       "1  Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.                                                                                                                                                                                      \n",
       "2  Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.                                                                                                                                                                                        \n",
       "3  Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.     \n",
       "4  Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics.\\nIn using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS).\\nBlack patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.   \n",
       "\n",
       "       Section  From  ...  Type    Annotation  \\\n",
       "0  Indications  112   ...  PREF  HYPERTENSION   \n",
       "1  Indications  112   ...  PREF  HYPERTENSION   \n",
       "2  Indications  112   ...  PREF  HYPERTENSION   \n",
       "3  Indications  74    ...  PREF  HYPERTENSION   \n",
       "4  Indications  74    ...  PREF  HYPERTENSION   \n",
       "\n",
       "                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               Context  \\\n",
       "0  Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\r\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.                                                                                                                                                                                        \n",
       "1  Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\r\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.                                                                                                                                                                                        \n",
       "2  Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined.\\r\\nMinoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs.                                                                                                                                                                                        \n",
       "3  Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics.\\r\\nIn using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS).\\r\\nBlack patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.   \n",
       "4  Benazepril hydrochloride tablets, USP are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics.\\r\\nIn using benazepril consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS).\\r\\nBlack patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks.   \n",
       "\n",
       "     DrugName           Drug_Brand_Name                                Set_ID  \\\n",
       "0  minoxidil   MINOXIDIL                 032835ab-1c8b-418a-9009-b6ebe58676dc   \n",
       "1  minoxidil   MINOXIDIL                 032835ab-1c8b-418a-9009-b6ebe58676dc   \n",
       "2  minoxidil   MINOXIDIL                 032835ab-1c8b-418a-9009-b6ebe58676dc   \n",
       "3  BENAZEPRIL  Benazepril Hydrochloride  8fdc8bda-635a-401f-a9b5-8a2a514b429e   \n",
       "4  BENAZEPRIL  Benazepril Hydrochloride  8fdc8bda-635a-401f-a9b5-8a2a514b429e   \n",
       "\n",
       "  Active_ingredient     UNII_ID WordCount   Drug_name  \n",
       "0  minoxidil         5965120SH1  102       Minoxidil   \n",
       "1  minoxidil         5965120SH1  102       Minoxidil   \n",
       "2  minoxidil         5965120SH1  102       Minoxidil   \n",
       "3  BENAZEPRIL        UDM7Q7QWP8  115       Benazepril  \n",
       "4  BENAZEPRIL        UDM7Q7QWP8  115       Benazepril  \n",
       "\n",
       "[5 rows x 21 columns]"
      ]
     },
     "execution_count": 80,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "match2.head()"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.8.3"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 4
}
